Skip to main navigation Skip to search Skip to main content

Clearance of xenon-133 from bone marrow in patients with small-cell lung cancer

L J Petersen, L Friberg, J Jensen, J Bülow, M Hansen, J Madsen

Abstract

The aim of this study was to estimate bone-marrow blood flow (BMBF) in man and to correlate this with myelosuppression induced by cytostatic treatment dosed as a function of surface area. Twenty-four patients suffering from small-cell lung cancer participated in the study. Blood flow was measured with the xenon-133 washout technique. The 133Xe clearance measurement took place in conjunction with the pre-treatment bone-marrow staging procedure (ad modern Radner). Tissue samples were taken for microscopy and for the determination of the blood-to-tissue partition coefficient lambda. After the bone-marrow aspiration, 0.1-0.2 ml of 133Xe in saline was injected into the bone marrow and the cannula was removed. Following a hyperaemic phase of 12 min (7-16 min), monoexponential washouts were demonstrated. The median washout rate constant was 0.0063 min-1 (0.0038-0.0098 min-1). Lambda values of 0.3-3.5 ml g were found, but microscopy of the bone marrow showed a fairly large admixture of peripheral blood. Therefore, the lambda values should be taken with caution and absolute blood-flow values were not calculated. The results demonstrated no correlation between 133Xe clearance from crista iliaca and leucocyte or platelet suppression.
Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Volume51
Issue number6
Pages (from-to)559-63
Number of pages5
ISSN0036-5513
Publication statusPublished - Oct 1991

Keywords

  • Aged
  • Antineoplastic Agents
  • Bone Marrow
  • Carcinoma, Small Cell
  • Female
  • Humans
  • Leukocyte Count
  • Lung Neoplasms
  • Male
  • Middle Aged
  • Platelet Count
  • Regional Blood Flow
  • Regression Analysis
  • Xenon Radioisotopes

Fingerprint

Dive into the research topics of 'Clearance of xenon-133 from bone marrow in patients with small-cell lung cancer'. Together they form a unique fingerprint.

Cite this